Form 6-K TORM plc For: Aug 31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number 001-38294
TORM plc
4th Floor, 120 Cannon Street, London, EC4N 6AS, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Attached to this Report on Form 6-K as Exhibit 99.1 is a copy of the press release of TORM plc (the “Company”), dated August 7, 2026, announcing that Oaktree Capital Group Holdings GP, LLC (“Oaktree”) has notified the Company that, following a change in ownership structure of OCM Njord Holdings S.à r.l. (“Njord Luxco”), Oaktree no longer indirectly holds any shares or voting rights in the Company as of July 31, 2026, and, as part of the transaction, Brookfield Corporation has become the ultimate controlling shareholder of Njord Luxco. Njord Luxco continues to hold an aggregate of 20,329,874 shares in the Company, which corresponds to 19.86 % of the total share capital and total voting rights in the Company.
The information contained in this Report on Form 6-K is hereby incorporated by reference into the Company’s registration statement on Form F-3 (File No. 333-283943) that was filed with the U.S. Securities and Exchange Commission effective December 19, 2024.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TORM PLC | |||
| Dated: August 7, 2026 | |||
| By: | /s/ Jacob Meldgaard | ||
| Jacob Meldgaard | |||
| Executive Director and Principal Executive Officer | |||
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TORM Plc. (TRMD) PT Raised to $38 at Evercore ISI
- Global Insured Catastrophe Losses Now Expected to Average $171 Billion Annually, Verisk Finds
- Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share